US Edition
New Large-Scale Study Maps Early Triggers of Alzheimer’s Protein Aggregation
- A team including members of the Wellcome Sanger Institute and affiliated research centers identified the early molecular processes that lead to amyloid protein aggregation in Alzheimer's disease, with their study published on June 11, 2025.
- This study followed the urgent need to understand amyloid beta aggregation, a key process in Alzheimer’s, amid limited treatments that mainly manage symptoms without halting progression.
- Using large-scale genomics and machine learning, the team analyzed over 140,000 protein variants to identify critical interactions in Aβ42 fibril formation, highlighting the C-terminal region as a therapeutic target.
- Dr. Benedetta Bolognesi described their novel "kinetic-selection" method as capturing rate-limiting aggregation steps in parallel, creating the first high-resolution map of amyloid beta mutation effects.
- The study offers a new framework for targeted Alzheimer's therapies and wider protein research, reflecting the need for more effective treatments as over 55 million people globally face dementia.
14 Articles
14 Articles
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects…
Scientists Have Developed a Synthetic “Mini Prion” That Mimics Alzheimer’s
The model enables the study of the fundamental interactions that underlie neurodegenerative disease. Researchers from Northwestern University and the University of California, Santa Barbara have engineered the first synthetic fragment of the tau protein that behaves like a prion, a type of misfolded protein known for its ability to propagate its abnormal shape to normal [...]
3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice
Alzheimer’s disease (AD) is a progressive, neurodegenerative dementia with no cure. Prominent hypotheses suggest accumulation of beta-amyloid (Aβ) contributes to neurodegeneration and memory loss, however identifying brain regions with early susceptibility to Aβ remains elusive. Using SWITCH to immunolabel intact brain, we created a spatiotemporal map of Aβ deposition in the 5XFAD mouse. We report that subcortical memory structures show primary …
UNC researchers to study Alzheimer's
Researchers at the University of North Carolina at Chapel Hill announced a $5 million federal grant to support groundbreaking research on potential treatments for Alzheimer's disease. The multi-year project aims to develop innovative therapies targeting early-stage cognitive decline and to…
New large-scale study maps early triggers of Alzheimer’s protein aggregation
A new large-scale study has mapped the first molecular events that drive the formation of harmful amyloid protein aggregates found in Alzheimer's disease, pointing towards a new potential therapeutic target.
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
